Considerations in the development of reversibly binding pet radioligands for brain imaging

Current Medicinal Chemistry

Volumn 23, Issue 18, 2016, Pages 1818-1869

  Pike, Victor W ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Blood brain barrier; Carbon 11; Efflux transporter; Fluorine 18; Molecular imaging; PET; Positron emitter; Radioligand

Indexed keywords

BRAIN PROTEIN; CARBON 11; FLUORINE 18; RADIOLIGAND; LIGAND; PROTEIN; RADIOISOTOPE;

AUTORADIOGRAPHY; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN TISSUE; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HUMAN; ISOTOPE LABELING; LIMIT OF QUANTITATION; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOLUME OF DISTRIBUTION; BRAIN; DIAGNOSTIC IMAGING; METABOLISM; PROCEDURES;

BRAIN; HUMANS; LIGANDS; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; PROTEINS; RADIOISOTOPES;

EID: 84978077114     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160418114826     Document Type: Review

References (387)

1. Imming, P.; Sinning, C.; Meyer, A. Drugs, their targets and the nature and number of drug targets. Nature Rev., 2007, 5, 821-834.
2. Heiss, W.D.; Herholz, K. Brain receptor imaging. J. Nucl. Med., 2006, 47, 302-312.
3. Politis, M.; Piccini, P. Positron emission tomography imaging in neurological disorders. J. Neurol., 2012, 259, 1769-1780.
4. Savitz, J.B.; Drevets, W.C. Neuroreceptor imaging in depression. Neurobiol. Dis., 2013, 52, 49-65.
5. Hargreaves, R.J. The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther., 2008, 83, 349-353.
6. Farde, L. The advantage of using positron emission tomography in drug research. Trends Neurosci., 1996, 19, 211-214.
7. Matthews, P.M.; Rabiner, E.A.; Passchier, J.; Gunn, R.N. Positron emission tomography molecular imaging for drug development. Br. J. Clin. Pharmacol., 2011, 73, 175-186.
8. Piel, M.; Vernaleken, I.; Rösch, F. Positron emission tomography in CNS drug discovery and drug monitoring. J. Med. Chem., 2014, 57, 9232-9258.
9. 99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur. J. Nucl. Med., 1997, 24, 372-380.
10. Guo, Y.; Chen, X.; Jia, H.; Ji, X.; Liu, B. Synthesis and biological evaluation of one novel technetium-99m-labeled nitroquipazine derivative as an imaging agent for serotonin transporter. Appl. Radiat. Isot., 2008, 66, 1804-1809.
11. Pike, V.W. Positron-emitting radioligands for studies in vivo - probes for human psychopharmacology. J. Psychopharmacology, 1993, 7, 139-158.
12. Kegeles, L.S.; Mann, J.J. In vivo imaging of neurotransmitter systems using radiolabeled receptor ligands. Neuropsychopharmacology, 1997, 17, 293-307.
13. Halldin, C.; Gulyás, B.; Langer, O.; Farde, L. Brain radioligands - state of the art and new trends. Q. J. Nucl. Med., 2001, 45, 139-152.
14. Laruelle, M.; Slifstein, M.; Huang, Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol. Imaging Biol., 2003, 5, 363-375.
15. Wong, D.F.; Pomper, M.G. Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems. Mol. Imaging Biol., 2003, 5, 350-362.
16. Eckelman, W.C.; Kilbourn, M.R.; Mathis, C.A. Discussion of targeting proteins in vivo: in vitro guidelines. Nucl. Med. Biol., 2006, 33, 449-451.
17. Patel, S.; Gibson, R. In vivo site-directed radiotracers: a mini-review. Nucl. Med. Biol., 2008, 35, 805-815.
18. van de Bittner, G.C.; Ricq, E.L.; Hooker, J.M. A philosophy of CNS radiotracer design. Acc. Chem. Res., 2014, 47, 3127-3134.
19. 18F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Neurosci. Bull., 2014, 30, 777-811.
20. Varnäs, K.; Varrone, A.; Farde, L. Modeling of PET data in CNS drug discovery and development. J. Pharmokinet. Pharmacodyn., 2013, 40, 267-279.
21. Gunn, R.N.; Slifstein, M.; Searle, G.E.; Price, J.C. Quantitative imaging of protein targets in the human brain with PET. Phys. Med. Biol., 2015, 60, R363-R411.
22. Mintun, M.A.; Raichle, M.E.; Kilbourn, M.R.; Wooten, G.F.; Welch, M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol., 1984, 15, 217-227.
23. Innis, R.B.; Cunningham, V.J.; Delforge, J.; Fujita, M.; Gjedde, A.; Gunn, R.N.; Holden, J.; Houle, S.; Huang, S.C.; Ichise, M.; Iida, H.; Ito, H.; Kimura, Y.; Koeppe, R.A.; Knudsen, G.M.; Knuuti, J.; Lammertsma, A.A.; Laruelle, M.; Logan, J.; Maguire, R.P.; Mintun, M.A.; Morris, E.D.; Parsey, R.; Price, J.C.; Slifstein, M.; Soss, V.; Suhara, T.; Votaw, J.R.; Wong, D.F.; Carson, R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab., 2007, 27, 1533-1539.
24. 11C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder. NeuroImage, 2012, 63, 1532-1541.
25. Lammertsma, A.A.; Hume, S.P. Simplified reference tissue model for PET receptor studies. NeuroImage, 1996, 4, 153-158.
26. Gunn, R.N.; Lammertsma, A.A.; Hume, S.P.; Cunningham, V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage, 1997, 6, 279-287.
27. 11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab.,1990, 10, 740-747.
28. Logan, J.; Fowler, J.S.; Volkow, N.D.; Wang, G.J.; Ding, Y.S.; Alexoff, D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab., 1996, 16, 834-840.
29. Logan, J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl. Med. Biol., 2000, 27, 661-670.
30. 11C-(R)-rolipram and the density of its target, phosphodiesterase-4, in the brains of conscious and anaesthetized rats. J. Nucl. Med., 2009, 50, 749-756.
31. 1A receptors in the primate brain. Psychopharmacology, 1997, 133, 196-202.
32. 2 receptor binding in the living human brain by PET. Science, 1986, 231, 258-261.
33. 11C]diprenorphine and positron emission tomography. J. Cereb. Blood Flow Metab., 1991, 11, 204-219.
34. D values with positron emission tomography. Eur. J. Pharmacol., 1992, 213, 107-115.
35. Delforge, J.; Spelle, L.; Bendriem, B.; Samson, Y.; Syrota, A. Parametric images of benzodiazepine receptor concentration using a partial-saturation injection. J. Cereb. Blood Flow Metab., 1997, 17, 343-355.
36. Shrestha, S.; Hirvonen, J.; Hines, C.S.; Henter, I.; Svenningsson, P.; Pike, V.W.; Innis, R.B. Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. NeuroImage, 2012, 59, 3243-3251.
37. Mathis, C.A.; Mason, N.S.; Lopresti, B.J.; Klunk, W.E. Development of positron emission tomography β-amyloid plaque imaging agents. Semin. Nucl. Med., 2012, 42, 423-432.
38. Kung, H.F. The β-amyloid hypothesis in Alzheimer's disease: seeing is believing. ACS Med. Chem. Lett., 2012, 3, 265-267.
39. Owen, D.R.J.; Matthews, P.M. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. Int. Rev. Neurobiol., 2011, 101, 19-39.
40. Kreisl, W.C.; Mbeo, G.; Fujita, M.; Zoghbi, S.S.; Pike, V.W.; Innis, R.B.; McArthur, J.C. Stroke incidentally identified using improved positron emission tomography for microglial activation. Arch. Neurol., 2009, 66, 1288-1289.
41. Hirvonen, J.; Kreisl, W.C.; Fujita, M.; Dustin, I.; Khan, O.; Appel, S.; Zhang, Y.; Morse, C.; Pike, V.W.; Innis, R.B.; Theodore, W.H. Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. J. Nucl. Med., 2012, 53, 234-240.
42. Kreisl, W.C.; Lyoo, C.H.; McGwier, M.; Snow, J.; Jenko, K.J.; Corona, W.; Morse, C.L.; Zoghbi, S.S.; Pike, V.W.; McMahon, F.J.; Turner R.S.; Innis, R.B.; Biomarkers Consortium PET Radioligand Project Team. PET radioligand binding to translocator protein correlates with severity of Alzheimer's disease and may mark conversion from mild cognitive impairment. Brain, 2013, 136, 2228-2238.
43. 11C]PBR28, two radioligands for translocator protein (18kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage, 2010, 49, 2024-2932.
44. Owen, D.R.; Yeo, A.J.; Gunn, R.N.; Song, K.; Wadsworth, G.; Lewis, A.; Rhodes, C.; Pulford, D.J.; Bennacef, I.; Parker, C.A.; St Jean, P.L.; Cardon, L.R.; Mooser, V.E.; Matthews, P.M.; Rabiner, E.A.; Rubio, J.P. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J. Cereb. Blood Flow Metab., 2012, 32, 1-5.
45. Kreisl, W.C.; Jenko, K.J.; Hines, C.S.; Lyoo, C.H.; Corona, W.; Morse C.L.; Zoghbi, S.S.; Hyde, T.; Kleinman, J.E.; Pike, V.W.; McMahon, F.J.; Innis, R.B.; Biomarkers Consortium PET Radioligand Project Team. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J. Cereb. Blood Flow Metab., 2013, 33, 53-58.
46. 3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J. Cereb. Blood Flow Metab., 2010, 30, 1608-1618.
47. Owen, D.R.J.; Gunn, R.N.; Rabiner, E.A.; Bennacef, I.; Fujita, M.; Kreisl, W.C.; Innis, R.B.; Pike, V.W.; Reynolds, R.; Matthews, P.M.; Parker, C.A. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J. Nucl. Med., 2011, 52, 24-32.
48. 1-methyl- 2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands. J. Med. Chem., 2011, 54, 366-373.
49. 18F]-FEPPA. J. Cereb. Blood Flow Metab., 2012, 32, 968-972.
50. Willeit, M.; Praschak-Rieder, N. Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: a review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. NeuroImage, 2010, 53, 878-892.
51. Hall, H.; Halldin, C.; Farde, L.; Sedvall, G. Whole hemisphere autoradiography of the postmortem human brain. Nucl. Med. Biol., 1998, 25, 715-719.
52. Varnäs, K.; Halldin, C.; Hall, H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Human Brain Mapping, 2004, 22, 246-260.
53. Långström, B.; Andrén, P.E.; Lindhe, Ö.; Svedberg, M.; Hall, H. In vitro imaging techniques in neurodegenerative diseases. Mol. Imaging Biol., 2007, 9, 161-175.
54. 11C]PIBamyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int., 2009, 54, 347-357.
55. 2 shows significant decreases in NET density in the human brain in Alzheimer's disease: a post mortem autoradiographic study. Neurochem. Int., 2010, 56, 789-798.
56. Young, A.B.; Frey, K.A.; Agranoff, B.W. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. In: In Vitro and In Vivo, Phelps, M.E.; Mazziotta, J.C.; Schelbert, H.R.; Eds.; Raven Press: New York, 1986, Ch 2. pp. 73-111.
57. Banay-Schwartz, M.; Kenessey, A.; De Guzman, T.; Lajtham, A.; Palkovits, M. Protein content of various regions of rat brain and adult and aging human brain. Age, 1992, 15, 51-54.
58. 3H]epibatidine. Brain Res., 1998, 801, 143-149.
59. 3H]epibatidine in vitro autoradiography. Neuroscience, 1998, 85, 1121-1133.
60. Cumming, P. Absolute abundances and affinity states of dopamine receptors in mammalian brain: a review. Synapse, 2011, 65, 892-909.
61. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int., 1997, 30, 565-574.
62. 4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol., 1995, 114, 993-998.
63. 4 binding site in human brain. J. Neural. Transm., 1998, 105, 575-586.
64. 6 receptors in rat, pig and human brain tissue. Br. J. Pharmacol., 2000, 130, 1597-1605.
65. 2 nicotinic acetylcholine receptors. Synapse, 2005, 55, 89-87.
66. 11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue form Alzheimer patients. Neurochem. Int., 2009, 54, 347-357.
67. 3H]Ro-15-1788 binding to benzodiazepine receptors in human post mortem brain homogenates. J. Neurochem., 1990, 55, 1310-1315.
68. 3H]sarmazenil in post-mortem human brain. Human Psychopharmacology, 1992, 7, 367-377.
69. 1 receptors is increased in patients with schizophrenia. Schizophrenia Res., 2012, 141, 185-188.
70. 1 receptor in human caudate and putamen. Neuropsychopharmacology, 1999, 21, 641-649.
71. 3H]raclopride to rat and human brain membranes. J. Neurochem., 1990, 55, 2048-2057.
72. 3H]raclopide in postmortem human brains. Brain Res., 1997, 765, 7-12.
73. 125I]RTI-55: in vitro binding and autoradiographic characterization. J. Neurochem., 1994, 62, 549-556.
74. Herdon, H.J.; Roberts, J.C.; Coulton, S.; Porter, R.A. Pharmacological characterization of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology, 2010, 59, 558-565.
75. 18F]F-PEB. Nucl. Med. Biol., 2007, 34, 1009-1017.
76. Pfeiffer, A.; Pasi, A.; Mehraein, P.; Herz, A. Opiate receptor binding sites in human brain. Brain Res., 1982, 248, 87-96.
77. Dean, B.; Scarr, E.; Pavey, G.; Copolov, D. Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder. J. Affect. Disord., 2003, 75, 65-69.
78. 1 receptor binding profile in gerbil and human brain. Br. J. Pharmacol., 2006, 148, 39-45.
79. 3H]RO5-4864 in human brain. Eur. J. Pharmacol., 1997, 340, 89-99.
80. Fujita, M.; Imaizumi, M.; Zoghbi, S.S.; Fujimura, Y.; Farris, A.G.; Suhara, T.; Hong, J.; Pike, V.W.; Innis, R.B. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. NeuroImage, 2008, 40, 43-52.
81. Bylund, D.B.; Teows, M.L. Radioligand binding methods - practical guide and tips. Am. J. Physiol., 1993, 265, L421-L429.
82. Cai, L.; Innis, R.B.; Pike, V.W. Radioligand development for PET imaging of β-amyloid (Aβ) - current status. Curr. Med. Chem., 2007, 14, 19-52.
83. Keen, M. Methods in Molecular Biology. Humana Press: Totowa, NJ; 1999, Vol. 106
84. 11C]raclopride with ultrahigh specific activity in rat brain determined by homogenate assay and autoradiography. Nucl. Med. Biol., 2008, 35, 19-27.
85. 18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40, 125-132.
86. 50) of an enzymatic reaction. Biochem. Pharmacol., 1973, 22, 3099-3108.
87. Hulme, E.C.; Trevethick, M.A. Ligand binding assays at equilibrium: validation and interpretation. Br. J. Pharmacol., 2010, 161, 1219-1237.
88. 2 receptors in nonhuman primates. Psychopharmacology, 2004, 175, 274-286.
89. 35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors. Br. J. Pharmacol., 2010, 161, 1238-1249.
90. Zhang, R.; Xie, X. Tools for GPCR drug discovery. Acta Pharmacologica Sinica, 2012, 33, 372-384.
91. de Jong, L.A.A.; Uges, D.R.A.; Franke, J.P.; Bischoff, R. Receptor-ligand binding assays: technologies and applications. J. Chromatogr. B, 2005, 829, 1-25.
92. 11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J. Cereb. Blood Flow Metab., 1999, 19, 1164-1173.
93. Horti, A.G.; Villemagne, V.L. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr. Radiopharm. Des., 2006, 12, 3877-3900.
94. Delforge, J.; Spelle, L.; Bendriem, B.; Samson, Y.; Bottlaender, M.; Papageorgiou, S.; Syrota, A. Quantitation of benzodiazepine receptors in human brain using the partial saturation method. J. Nucl. Med., 1996, 37, 5-11.
95. 1 dopamine receptor binding in neuroleptic-naïve patients with schizophrenia. Am. J. Psychiatry, 2002, 159, 761-767.
96. 2 dopamine receptors in neuroleptic-naïve schizophrenic patients. Arch. Gen. Psychiatry, 1990, 47, 213-219.
97. 11C]-raclopride in vivo: a testretest analysis. J. Cereb. Blood Flow Metab., 1999, 19, 210-217.
98. 2 receptor density and affinity in the human brain measured by 3D PET. Int. J. Neuropsychopharmacology, 1999, 2, 734-782.
99. Guo, Q, Brady, M.; Gunn, R.N. A biomathematical modeling approach to central nervous system radioligand discovery and development. J. Nucl. Med., 2009, 50, 1715-1723.
100. Pike, V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol. Sci., 2009, 30, 431-440.
101. 2A receptors: a PET study in healthy human subjects. J. Cereb. Blood Flow Metab., 2007, 27, 1733-1741.
102. Huang, Y.; Zheng, M.-Q.; Gerdes, J.M. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr. Top. Med. Chem., 2010, 10, 1499-1526.
103. Schafer, K.N.; Kim, S.; Matzavinos, A.; Kuret, J. Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer's disease: a simulation study. NeuroImage, 2012, 60, 1724-1733.
104. Donohue, S.R.; Dannals, R.F.; Halldin, C.; Pike, V.W. N- (4-Cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors. J. Med. Chem., 2011, 54, 2961-2970.
105. 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J. Med. Chem., 2008, 51, 17-30.
106. 18F-labeled ligand for imaging brain peripheral benzodiazepine receptors with PET. J. Med. Chem., 2009, 52, 688-699.
107. 18F] FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1). J. Med. Chem., 2013, 56, 9146-9155.
108. Pike, V.W.; Halldin, C.; Crouzel, C.; Barré, L. Nutt, D.J.; Osman, S.; Shah, F.; Turton, D.R.; Waters, S.L. Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites - current status. Nucl. Med. Biol., 1993, 20, 503-525.
109. López-Romero, B.; Evrard, G.; Durant, F.; Sevrin, M.; George, P. Molecular structure and stereoelectronic properties of sarmazenil - a weak inverse agonist at the omega modulatory sites (benzodiazepine receptors): comparison with bretazenil and flumazenil. Bioorg. Med. Chem., 1998, 6, 1745-1757.
110. Kenakin, T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol., 2004, 65, 2-11.
111. Park, P.S.-H. Ensemble of G-protein-coupled receptor active states. Curr. Med. Chem., 2012, 19, 1146-1154.
112. 1A receptors and intrinsic activity. Eur. J. Pharmacol., 1999, 386, 97-103.
113. 1A receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems. Br. J. Pharmacol., 2000, 130, 1108-1114.
114. 2C receptors: evidence favouring the ternary complex and two-state models of agonist action. J. Neurochem., 1999, 72, 2127-2134.
115. Kearn, C.S.; Greenberg, M.J.; Di Camelli, R.; Kurzawa, K.; Hlllard, C.J. Relationship between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem., 1999, 72, 2379-2387.
116. 2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol. Pharmacol., 1992, 42, 432-438.
117. Kobilka, B.K.; Deupi, X. Conformational complexity of Gprotein-coupled receptors. Trends Pharm. Sci., 2007, 28, 397-406.
118. Rosenbaum, D.M.; Rasmussen, S.G.F.; Kobilka, B.K. The structure and function of G-protein-coupled receptors. Nature, 2009, 459, 356-363.
119. Deupi, X.; Kobilka, B.K. Energy landscapes as a tool to integrate GPCR structure, dynamics and function. Physiology, 2010, 25, 293-303.
120. 1A receptors in vivo. Prog. Med. Chem., 2001, 38, 189-247.
121. 11C]WAY-100635. Eur. J. Pharmacol., 1995, 283, R1-R3.
122. 11C]WAY-100635. Eur. J. Pharmacol., 1996, 301, R5-R7.
123. Farde, L.; Ito, H.; Swahn, C.-G.; Pike, V.W.; Halldin, C. Quantitative analyses of carbonyl-carbon-11 WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J. Nucl. Med., 1998, 39, 1965-1971.
124. 11C]WAY-100635 for PET. Neuro-Image, 1998, 8, 426-440.
125. 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)- 4-methyl-1,2,4-triazine-3, 5(2H,4H)dione in nonhuman primates. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1050-1060.
126. 18F-FCWAY. PloS One, 2015, 10(4) e0121342.
127. 1A receptors with PET. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1670-1682.
128. 1A receptors in rat brain membranes. Eur. J. Pharmacol., 1995, 288, 173-186.
129. 11C-CUMI-101, an agonist PET radiotracer. J. Nucl. Med., 2010, 51, 1892-1900.
130. 1A receptor ligand, CUMI-101 (MMP), in rat brain tissue. Nucl. Med. Biol., 2011, 38, 273-277.
131. 1 adrenoceptors in brain. J. Nucl. Med., 2014, 55, 141-146.
132. 3 receptors in vivo with positron emission tomography. Curr. Top. Med. Chem., 2010, 10, 1477-1498.
133. 11C]raclopride. Synapse, 2006, 59, 260-269.
134. 2 receptor in vivo: fact or fiction? Biochem. Pharmacol., 2011, 83, 193-198.
135. 2 receptors: methods of detection and clinical implications. Naunyn-Schmiederberg's Arch. Pharmacol., 2013, 386, 135-154.
136. 11C]- raclopride. J. Pharmacol. Exp. Ther., 2005, 315, 80-90.
137. 2 receptors in vivo using positron emission tomography. J. Neurochem., 2006, 97, 1089-1103.
138. Seeman, P. Dopamine agonist radioligand binds to both D2high and D2low receptors, explaining why alterations in D2high are not detected in human brain scans. Synapse, 2012, 66, 88-93.
139. Frost, J.J.; Douglass, K.; Mayberg, H.; Dannals, R.F.; Links, J.; Wilson, A.; Ravert, H.; Wagner, H.N. Multicompartmental analysis of C-11 carfentanil binding to opiate receptors in man by positron emission tomography. J. Nucl. Med., 1986, 27, 1027-1027.
140. 1 receptors in human and monkey brains using F-18-labeled inverse agonist radioligands. J. Nucl. Med., 2010, 51,112-120.
141. 11C]Ro15-4513 in human brain measured with PET. Neurosci. Lett., 1992, 145, 133-136.
142. Highfield Nickols, H.; Conn, P.J. Development of allosteric modulators of GPCRs for treatment. Neurobiol. Dis., 2014, 61, 55-71.
143. Melancon, B.J.; Hopkins, C.R.; Wood, M.R.; Emmitte, M.R,. Emmitte, K.A.; Niswender, C.M.; Christopoulos, A.; Conn, P.J.; Lindsley, C.W. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J. Med. Chem., 2012, 55, 1445-1464.
144. Mu, L.; Schubiger, P.A.; Ametamey, S.M. Radioligands for the PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5). Curr. Top. Med. Chem., 2010, 10, 1558-1568.
145. Zanotti-Fregonara, P.; Zhang, Y.; Jenko, J.J.; Gladding, R.L.; Zoghbi, S.S.; Fujita, M.; Sbardella, G.; Castellano, S.; Taliani, S.; Martini, C.; Innis, R.B.; Da Settimo, F.; Pike, V.W. Synthesis and evaluation of translocator 18 kDa protein (TSPO) positron emission tomography (PET) radioligands with low binding sensitivity to human single nucleotide polymorphism rs6971. ACS Chem. Neurosci., 2014, 5, 963-971.
146. 11C]ER176, a radioligand for TSPO, is sensitive to a genetic polymorphism in vivo but not in vitro. (Submitted).
147. 1 receptors. NeuroImage, 2014, 84, 733-741.
148. 11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. NeuroImage, 2008, 39, 1289-1298.
149. 11C-PBR28 to translocator protein (18 kDa) in the human brain. J. Nucl. Med., 2013, 54, 64-69.
150. 11C-labeled aryloxyanilide analogs to measure translocator protein in human brain using positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 352-357.
151. Imaizumi, M.; Briard, E.; Zoghbi, S.S.; Gourley, J.P.; Hong, J.; Musachio, J.L.; Gladding, R.; Pike, V.W.; Innis, R.B.; Fujita, M. Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptors in brain. Synapse, 2007, 61, 595-605.
152. 4 receptors. Synapse, 2014, 68, 613-623.
153. 18F-PBR06. J. Nucl. Med., 2009, 50, 1047-1053.
154. 11C](R)-(-)-RWAY. Synapse, 2006, 60, 510-520.
155. Shrestha, S.S.; Nelson, E.E.; Liow, J.S.; Gladding, R.; Lyoo, C.H.; Noble, P.L.; Morse, C.; Henter, I.D.; Kruger, J.; Zhang, B.; Suomi, S.J.; Svenningsson, P.; Pike, V.W.; Winslow, J.T.; Leibenluft, E.; Pine, D.S.; Innis, R.B. Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am. J. Psychiatry, 2014, 171, 323-331.
156. 11C](R)-(-)-RWAY: radiometabolite(s) likely confound brain measurements. Synapse, 2007, 61, 469-477.
157. 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol. Psychiatry 2012, 72, 548-554.
158. 11C](R)- rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function. NeuroImage, 2011, 54, 1903-1909.
159. 18F-labeled positron emission tomography radioligand for brain histamine subtype-3 receptors based on a non-imidazole 2-aminoethylbenzofuran chemotype. J. Med. Chem., 2012, 55, 2406-2415.
160. Pike, V.W.; Rash, K.S.; Chen, Z.; Pedregal, C.; Statnick, M.A.; Kimura, Y.; Hong, J.; Zoghbi, S.S.; Fujita, M.; Toledo, M.A.; Diaz, N.; Gackenheimer, S.L.; Tauscher, J.T.; Barth, V.N.; Innis, R.B. Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. J. Med. Chem., 2011, 54, 2687-2700.
161. 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide (NOP) receptors. J. Nucl. Med., 2011, 52, 1638-1645.
162. 11C-NOP-1A. J. Nucl. Med., 2012, 53, 385-392.
163. 11C]NOP- 1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. NeuroImage, 2014, 87, 89-95.
164. 1 receptors in nonhuman primate brain. Neuropsychopharmacology, 2008, 33, 259-269.
165. 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl) benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. J. Med. Chem., 2007, 50, 3256-3266.
166. Brown, A.K.; Kimura, Y.; Zoghbi, S.S.; Siméon F.G.; Liow, J.S.; Kreisl, W.C.; Taku, A.; Fujita, M.; Pike, V.W.; Innis, R.B. Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J. Nucl. Med., 2008, 49, 2042-2048.
167. 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J. Nucl. Med., 2006, 47, 520-527.
168. st ed.; Wiley-Interscience: New York 1979.
169. van de Waterbeemd, H.; Camenish, G.; Folkers, G.; Chretien, J.R.; Raevsky, O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and Hbonding descriptors. J. Drug Targeting, 1998, 6, 151-165.
170. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23, 3-26.
171. Kelder, J.; Grootenhuis, P.D.J.; Byada, D.M.; Delbressine, L.P.C.; Ploemen, J.P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res., 1999, 16, 1514-1519.
172. Norinder, U.; Haeberlein, M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Delivery Rev., 2002, 54, 291-313.
173. Hitchock, S.A.; Pennington, L.D. Structure-brain exposure relationships. J. Med. Chem., 2006, 49, 7559-7583.
174. Gleeson, M.P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem., 2008, 51, 817-834.
175. Zhang. L.; Villabos, A.; Beck, E.M.; Bocan, T.; Chappie, T.A.; Chen, L.; Grimwood, S.; Heck, S.D.; Helal, C.J.; Hou, X.; Humphrey, J.M.; Lu, J.; Skaddan, M.B.; McCarthy, T.J.; Verhoest, P.R.; Wager, T.T.; Zasadny, K. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligand and their application in the development of a novel phosphodiesterase 2A PET ligand. J. Med. Chem., 2013, 56, 4568-4579.
176. Zoghbi, S.S.; Anderson, K.B.; Jenko, K.J.; Luckenbaugh, D.A.; Innis, R.B.; Pike, V.W. On quantitative relationships between drug-like compound lipophilicity and plasma free fraction in monkey and human. J. Pharm. Sci., 2012, 101, 1028-1039.
177. Abbot, N.J.; Chugani, D.C.; Zaharchuk, G.; Rosen, B.R.; Lo, E.H. Delivery of imaging agents into brain. Adv. Drug Deliv. Rev., 1999, 37, 253-277.
178. Waterhouse, R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging targets. Mol. Imaging Biol., 2003, 5, 376-389.
179. Rankovic, Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J. Med. Chem., 2015, 58, 2584-2608.
180. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem., 2000, 43, 3714-3717.
181. Clark, D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci., 1999, 88, 815-821.
182. Rishton, G.M.; La Bonte, K.; Williams, A.J.; Kassa, K.; Kolanov, E. Computational approaches to the prediction of blood-brain barrier permeability: a comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr. Opin. Drug Disc. Dev., 2006, 9, 303-313.
183. Gerebtzoff, G.; Seelig, A. In silico prediction of blood-brain barrier permeation using the calculated molecular crosssectional area as main parameter. J. Chem. Inf. Model, 2006, 46, 2638-2650.
184. Adenot, M.; Lahana, R. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates. J. Comput. Inf. Comput. Sci., 2004, 44, 239-248.
185. Hammarlund-Udenaes, M.; Fridén, M.; Syvänen, S.; Gupta, A. On the rate and extent of drug delivery to the brain. Pharm. Res., 2007, 25, 1737-1750.
186. Deo, A.K.; Theil, F.P.; Nicolas, J.M. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol. Pharmaceutics, 2013, 10, 1581-1595.
187. ACD/Labs data sheet. Available from: http://www.acdlabs.com/download/docs/datasheets/datasheet-bbb.pdf. Last accessed 01/19/2016
188. Stieger, B.; Gao, B. Drug transporters in the central nervous system. Clin. Pharmacokinet., 2015, 54, 225-242.
189. Xia, C.Q.; Xiao, G.; Liu, N.; Pimprale, S.; Fox, L.; Patten, C.J.; Crespi, C.L.; Miwa, G.; Gan, L.S. Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using ATPase activity assays. Mol. Pharm., 2006, 3, 78-86.
190. Syvänen, S.; Lindhe, O.; Palner, M.; Kornum, B.R.; Rahman, O.; Långström, B.; Knudsen, G.M.; Hammarlund-Udenaes, M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab. Dispos., 2009, 37, 635-643.
191. Doze, P.; van Waarde, A.; Elsinga, P.H.; Hendrikse, N.H.; Vaalburg, W. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the bloodbrain-barrier. Synapse, 2000, 36, 66-74.
192. 18F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transporters at the human blood-brain barrier. J. Nucl. Med. (In press).
193. Elsinga, P.H.; Hendrikse, N.H.; Bart, J.; van Waarde, A.; Vaalburg, W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol. Imaging Biol., 2005, 7, 37-44
194. 18F]MPPF: a pharmacokinetic study in mice and non-human primates. Pharm. Res., 2012, 29, 2468-2476.
195. 18F]MPPF in rats. Eur J. Pharmacol., 2000, 407, 273-280.
196. 18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 2256-2266.
197. Tournier, N.; Valette, H.; Peyronneau, M.-A.; Saba, W.; Goutla, S.; Kuhnast, B.; Dollé, F.; Scherrmann, J.-M.; Cisternino S.; Bottlaender, M. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J. Nucl. Med., 2011, 52, 415-423.
198. 11C](R) (-)-RWAY. Synapse, 2007, 61, 96-105.
199. 2A receptor densities in the rat brain. Nucl. Med. Biol., 2014, 41, 1-9.
200. 18F]MH.HZ. Neuropsychobiology, 2011, 63, 183-190.
201. Ishiwata, K.; Kawamura, K.; Yanai, K.; Hendrikse, N.H. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J. Nucl. Med., 2007, 48, 81-87.
202. 11C]flumazenil and PET. J. Nucl. Med., 2012, 53, 1974-1983.
203. 1 receptors in rodents. NeuroImage, 2008, 41 690-698.
204. 18F]fallypride in microPET imaging studies. Neuropharmacology, 2014, 84, 152-158.
205. 11C]Befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats. Eur. J. Pharm. Sci., 2013, 50, 520-525.
206. 1 receptor) antagonists SR 1403433 and GR 205171: a comparative study using mdr1a-/- and mdr1a+/+ mice. Behav. Pharmacol., 2003, 14, 457-463.
207. Kreisl, W.C.; Bhatia, R; Morse, C.L.; Woock, A.E.; Zoghbi, S.S.; Shetty, H.U.; Pike, V.W.; Innis, R.B. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar J. Nucl. Med., 2015, 56, 82-87.
208. Ecker, G.F.; Stockner, T.; Chiba, P. Computational models for prediction of interactions with ABC-transporters. Drug Discov. Today, 2008, 13, 311-317.
209. Demel, M.A.; Kraemer O.; Ettmayer, P.; Haaksma, E.; Ecker, G.F. Ensemble rule-based classification of substrates of the human ABC-transporter ABCB1 using simple physiochemical descriptors. Mol. Inf., 2010, 29, 233-242.
210. Seelig, A. A general pattern for substrate recognition by Pglycoprotein. Eur. J. Biochem., 1998, 251, 252-261.
211. Seelig, A.; Gatlik-Landwojtowicz, E. Inhibitors of multidrug efflux transporters: their membrane and protein interactions. Mini-Rev. Med. Chem., 2005, 5, 135-151.
212. Hitchcock, S.A. Structural modifications that alter the Pglycoprotein efflux properties of compounds. J. Med. Chem., 2012, 55, 4877-4895.
213. Desai, P.V.; Sawada, G.A.; Watson, I.A.; Raub, T.J. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. Mol. Pharm., 2013, 10, 1249-1261.
214. Didziapetris, R.; Japertas, P.; Avdeef, A.; Petrauskas, A. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target., 2003, 11, 391-406.
215. Kalvass, J.C.; Maurer, T.S., Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos. 2002, 23, 327-338.
216. Summerfield, S.G.; Stevens, A.J.; Cutler, L., del Carmen, O.M.; Hammond, P.; Tang, S.P.; Hersey, A. Spaldinh, D.J.; Jeffrey, P. Improving the in vitro prediction of the in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther., 2006, 316, 1282-1290.
217. Gandelman, M.S.; Baldwin, R.M.; Zoghbi, S.S.; Zea-Ponce, Y.; Innis R.B. Evaluation of ultrafiltration for the freefraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J. Pharm. Sci., 1994, 83, 1014-1019.
218. Gleeson, M.P. Plasma protein binding affinity and its relationship to molecular structure: and in silico analysis. J. Med. Chem., 2007, 50, 101-112.
219. Gunn, R.N.; Summerfield, S.G.; Salinas, C.A., Read, K.D.; Guo, Q.; Searle, G.E.; Parker, C.A.; Jeffrey, P.; Laruelle, M. Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J. Cereb. Blood Flow Metab., 2012, 32, 874-883.
220. Summerfield, S.G.; Lucas, A.J.; Porter, R.A.; Jeffrey. P.; Gunn. R.N.; Read, K.R.; Stevens, A.J.; Metcalf, A. C.; Osuna, M.C.; Kilford, P.J.; Passchier, J.; Ruffo, A.D. Toward an improved prediction of human in vivo brain penetration. Xenobiotica, 2008, 38, 1518-1535.
221. Man ICORPTGOR. Report of the Task Group on Reference Man. Pergamon Press: Oxford; 1975.
222. 1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. Nucl. Med. Biol., 2011, 38, 261-272.
223. Assmus, F.; Seelig, A.; Gobbi L.; Borroni E.; Glaaentzlin, P.; Fischer, H. Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates. Eur. J. Pharm. Sci., 2015, 79, 27-35.
224. Rosso, L.; Gee, A.D.; Gould, I.R. Ab initio computational study of positron emission tomography ligands interacting with lipid molecule for the prediction of nonspecific binding. J. Comput. Chem., 2008, 29, 2397-2405.
225. Kannan, P., Brimacombe, K.R.; Kreisl, W.C.; Liow, J-S., Zoghbi, S.S.; Telu, S.; Zhang, Y.; Pike, V.W.; Halldin, C.; Gottesman, M.M.; Innis, R.B.; Hall, M.D. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc. Natl. Acad. Sci., USA, 2011, 108, 2593-2598.
226. 11C]flumazenil and PET: application of the steady-state principle. J. Cereb. Blood Flow Metab., 1995, 15, 152-165.
227. Cunningham, V.J.; Rabiner, E.A.; Slifstein, M.; Laruelle M.; Gunn, R.N. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J. Cereb. Blood Flow Metab., 2010, 30, 46-50.
228. 18F-FIMX images and quantifies metabotropic glutamate receptor 1 in proportion to the regional density of its gene transcript in human brain. J. Nucl. Med., 2016, 57, 242-247.
229. 18F]altanserin. J. Nucl. Med., 2000, 41, 234-241.
230. Liptrot, M.; Adams, K.H.; Martiny, L.; Pinborg, L.H.; Lonsdale, M.N.; Olsen, N.V.; Holm, S.; Svarer, C.; Knudsen, G.M. Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. Neuroimage, 2004, 21, 483-493.
231. 11C] β-CIT labelled in two different positions. Nucl. Med. Biol., 1999, 26, 343-350.
232. 18F]altanserin in human and rodent. Nucl. Med. Biol., 1999, 26, 601-608.
233. 11C-Labelling of dimethylphenethylamine in two different positions and biodistribution studies. Appl. Radiat. Isot., 1989, 40, 557-560.
234. 11C[MADAM. Nucl. Med. Biol., 2014, 41, 501-506.
235. 11C]PE2I. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 667-678.
236. 11C]PE2I binding to the dopamine transporter - application to juvenile myoclonic epilepsy. Neuroimage, 2012, 59, 3582-3593.
237. 11C]WAY-100635, in monkey and human plasma by HPLC - comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl. Med. Biol., 1996, 23, 627-634.
238. 11C]WAY-100635 - explanation of high signal in PET and an aid to biomathematical modelling. Nucl. Med. Biol., 1998, 25, 215-223.
239. 11C]flumazenil. Neuroimage, 2009, 45, 891-902.
240. 11C] labelling: part II: metabolism studies. Nucl. Med. Biol., 2012, 39, 347-359.
241. 11C] labelling part I: PET studies. Nucl. Med. Biol., 2012, 39, 227-233.
242. 18F]FPEB with bolus plus constant infusion in humans. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42, 1530-1541.
243. 1A receptor antagonists 3-trans-FCWAY and 3-cis-FCWAY. Nucl. Med. Biol., 2006, 33, 1013-1019.
244. 11C]MeNER in humans, monkeys and rats. Mol. Imaging Biol., 2009, 11, 23-30.
245. 11CLoperamide and its desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J. Nucl. Med., 2008, 49, 648-656.
246. 11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J. Med. Chem., 2008, 51, 6034-6043.
247. 18F) injection in healthy Japanese adult volunteers. Ann. Nucl. Med., 2015, 29, 627-635.
248. 18F]MPPF. J. Nucl. Med., 2000, 41, 1830-1835.
249. 2 receptors in humans using positron emission tomography. Eur. J. Nucl. Med., 1994, 21, 937-946.
250. 18FFPEB in humans. J. Nucl. Med., 2014, 55, 1119-1121.
251. 18F]FA-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J., 2003, 17, 1331-1333.
252. 18F-fluoro-A-85380 in healthy volunteers. J. Nucl. Med., 2003, 44, 596-601.
253. 18F]MK-6577 in humans. Synapse, 2015, 69, 33-40.
254. 18F-AZAN, a radioligand with optimal brain kinetics. J. Nucl. Med., 2013, 54, 1308-1314.
255. 18F]-T807. J. Alzheimer's Dis., 2013, 34, 457-468.
256. 18F]flubatine. NeuroImage, 2015, 118, 199-208.
257. 18F]Fluoro-A- 85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse, 2004, 53, 184-189.
258. 18F]UCB-H: first-in-human study. Mol. Imaging Biol., 2015, 17, 557-564.
259. 18F]SP203, to image metabotropic glutamate subtype 5 receptors in humans. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 1943-1949.
260. 2 receptor density and affinity in the human brain using PET. Neuroimage, 2004, 22, 794-803.
261. 2: a human whole body PET study. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 630-636.
262. 18F]SPARQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J. Nucl. Med., 2007, 48, 100-107.
263. 18F-labelled fluoromethyl-McN5652 and PET in humans. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 1001-1011.
264. 18F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl. Med. Biol., 2012, 39, 570-578.
265. 18F-654. J. Nucl. Med., 2014, 55, 1297-1304.
266. 18FMNI- 444, a PET radiotracer for brain adenosine 2A receptors. J. Nucl. Med., 2015, 56, 586-591.
267. 18F]MK- 9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci., USA, 2007, 104, 9800-9805.
268. 18F-fluoroethoxy benzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. J. Nucl. Med., 2014, 55, 396-404.
269. 18F]- FEPPA, to image translocator protein (18 kDa). Mol. Imaging Biol., 2013, 156, 353-359.
270. Villemagne, V.L.; Furumoto, S.; Fodero-Tavoletti, M.T.; Mulligan, R.S.; Hodges, J.; Harada, R.; Yates, P.; Piguet, O.; Pejoska, S.; Doré, V.; Yanai, K.; Masters, C.L.; Kudo, Y.; Rowe, C.C.; Okamura, N. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41, 816-826.
271. 18F-FE-SPA-RQ. J. Nucl. Med., 2008, 49, 1749-1755.
272. 18F]FEDAA1106. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 2058-2065.
273. 18F]FACT in human brain. Nucl. Med. Biol., 2015, 42, 734-744.
274. Lin, J.J.; Hsu, W.C.; Hsiao, I.T.; Wey, S.P.; Jin, L.-W.; Skovronsky, D.; Wai, Y.Y.; Chang, H.P.; Lo, C.W.; Yao, C.H.; Yen, T.C.; Kung, M.P. Whole body distribution and brain PET imaging with AV-45, a novel amyloid imaging agent - a pilot study. Nucl. Med. Biol., 2010, 37, 497-508.
275. 18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J. Nucl. Med., 2010, 51, 1480-1485.
276. 18F-FCWAY. PloS One, 2015, DOI:10.1371/journal.pone. 0121342
277. 18F-Mefway, a PET radioligand specific to serotonin-1A receptors. J. Nucl. Med., 2014, 55, 1973-1979.
278. 18FPBR06, to image translocator protein (18 kDa). J. Nucl. Med., 2010, 51, 145-149.
279. 18F]FECNT PET in healthy humans. Nucl. Med. Biol., 2014, 41, 217-222.
280. 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40, 254-261.
281. 18F-CPFPX determined from whole-body PET. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1499-1506.
282. Kazumata, K.; Dhawan, V.; Chaly, T.; Antonini, A.; Margouleff, C.; Belakhlef, A.; Neumeyer, J.; Eidelberg, D. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J. Nucl. Med., 1998, 39, 1521-1530.
283. 18F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. J. Nucl. Med., 2011, 52, 1313-1321.
284. 1A receptors in human brain. J. Nucl. Med., 2007, 48, 1154-1161.
285. 18F]CPFPX by CYP1A2: implications for bolus/infusion studies. Nucl. Med. Biol., 2006, 33, 891-898.
286. 11C]SKF 82957. Nucl. Med. Biol., 2010, 37, 837-843.
287. 18Flabeled fluoroacetylmorpholino derivative of vesamicol for neuroimaging of the vesicular acetylcholine transporter. Nucl. Med. Biol., 2008, 35, 185-195.
288. 13N radiolabels for positron emission tomography. Angew. Chem. Int. Ed., 2008, 47, 8998-9033.
289. Ferrieri, R.A. In: Handbook of Radiopharmaceuticals. Welch, M.J.; Redvanly, C.S. Eds.; Wiley & Sons Ltd: Chichester: 2003, Ch: 75. pp. 229-282.
290. Antoni, G.; Kihlberg, T.; Långström, B. In: Handbook of Radiopharmaceuticals. Welch, M.J.; Redvanly, C.S., Eds.; Wiley & Sons Ltd, Chichester: 2003, Ch 5. pp 141-194.
291. 11C-labeled radiotracers synthesis. Curr. Med. Chem., 2008, 15, 235-277.
292. Henriksen, G. In: Munich Molecular Imaging Handbook Series. Vol. 1. Scintomics Print Media and Publishing: Fürstenfeldbruck, 2010; Ch. 2, pp. 75-101.
293. 11C chemistry reviews - surveying and filling the gaps. Curr. Org. Chem., 2013, 17, 2067-2096.
294. Snyder, S.E.; Kilbourn, M.R. In: Handbook of Radiopharmaceuticals. Welch, M.J.; Redvanly, C.S., Eds.; Wiley & Sons Ltd: Chichester; 2003, Ch 6. pp. 195-227.
295. Schirrmacher, R.; Wangler, C.; Schirrmacher, E. Recent developments and trends in F-18-radiochemistry: syntheses and applications. Mini-Rev. Org. Chem., 2007, 4, 317-329.
296. 18F]fluoride ion. Eur. J. Org. Chem., 2008, 2008(17), 2853-2873.
297. Schirrmacher, R.; Wängler, C.; Schirrmacher, E. In: Munich Molecular Imaging Handbook Series. Vol 1. Scintomics Print Media and Publishing: Fürstenfeldbruck, 2010, Ch. 1, pp. 5-73.
298. Cole, E.; Stewart, M.; Littich, R.; Hoareau, R.; Scott, P.J.H. Radiosyntheses using fluorine-18: the art and science of late stage fluorination. Curr. Topics Med. Chem., 2014, 14, 875-900.
299. 18F]fluorination: new solutions to old problems. Chem. Sci., 2014, 5, 4545-4553.
300. Jacobson, O.; Kiesewetter, D.O.; Chen, X. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjugate Chem., 2015, 26, 1-18.
301. 11C]SB2017145. Nucl. Med. Biol., 2011, 38, 1085-1091.
302. Hume, S.P.; Gunn, R.N.; Jones, T. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur. J. Nucl. Med., 1998, 25, 173-176.
303. Jagoda, E.M.; Vaquero, J.J.; Seidel, J.; Green, M.V.; Eckelman, W.C. Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nucl. Med. Biol., 2004, 31, 771-779.
304. 11C-carbon dioxide from a nitrogen gas target. J. Nucl. Med., 1972, 13, 429-430.
305. Gómez-Vallejo, V.; Gaja, V.; Koziorowski, J.; Lllop, J. In: Positron Emission Tomography - Current Clinical and Research Aspects. Hsieh C.-H.; Ed. Rijeka: InTech; 2012, Ch. 7., pp. 183-210.
306. Lapi, S.E.; Welch, M.J. A historical perspective on the specific activity of radiopharmaceuticals: what have we learned in the 35 years of the ISRC. Nucl. Med. Biol., 2013, 40, 314-320.
307. 2 gas target: effect of irradiation dose, irradiation history, oxygen content and beam energy. Radiochim. Acta, 2000, 88, 211-215.
308. 11CMethane production in small volume, high pressure gas targets. Radiochim. Acta, 2000, 88, 201-205.
309. 11C]methane: increased specific radioactivity. Appl. Radiat. Isot., 2009, 67, 106-110.
310. 11C reaction, (XV). Int. J. Appl. Radiat. Isot., 1975, 26, 435-442.
311. 11C]methane. Appl. Radiat. Isot., 1989, 40, 265-266.
312. 2 fixation: a renaissance in PET radiochemistry. Chem. Commun., 2013, 49, 5621-5629.
313. 11C-labeled carboxylic acids. Angew. Chem. Int. Ed., 2012, 51, 2698-2702.
314. 11C]carbon dioxide. Appl. Radiat. Isot., 1989, 40, 425-427.
315. 2 for the synthesis of PET radiotracers. Eur. J. Org. Chem., 2015, 6434-6438.
316. 2 into aliphatic and aromatic amines. Chem. Commun., 2013, 49, 8193-8195.
317. 2 into carbamates. Angew. Chem. Int. Ed., 2009, 48, 3482-3485.
318. Wuest, F.; Berntd, M.; Kiess, T. In: PET Chemistry the Driving Force in Molecular Imaging. Schubiger, P.A.; Lehmann L.; Friebe, M., Eds.; Springer: New York; 2007, Ch. 7, pp. 183-214.
319. 11C. Int. J. Appl. Radiat. Isot., 1977, 28, 49-52. [
320. 11C]methyl iodide. Appl. Radiat. Isot., 1987, 38, 601-603.
321. 11C]methyl iodide: a search for the source of carrier carbon. Appl. Radiat. Isot., 1988, 39, 1-7.
322. 3I synthesized by the wet method; main sources of noradioactive carbon. Appl. Radiat. Isot., 2008, 67, 111-114.
323. 2. Nucl. Med. Biol., 1997, 24, 93-97.
324. Larsen, P.; Ulin, J.; Dahlstrom, K.; Jensen, M. Synthesis of C-11 iodomethane by iodination of C-11 methane. Appl. Radiat. Isot., 1997, 48, 153-157.
325. 3I through gas phase iodination reaction using a TRACERlab FX(C) synthesis module. Appl. Radiat. Isot., 2008, 66, 482-488.
326. 11C]FLB 457 by use of the GE medical systems PETtrace MeIMicroLab. J. Label. Compd. Radiopharm., 2000, 43, 331-338.
327. 11C]iodomethane: a remarkably simple captive solvent method. Nucl. Med. Biol., 2000, 27, 529-532.
328. 11C]- methylation reactions J. Label. Compd. Radiopharm., 2009, 52, 490-492.
329. 11C]methyl triflate. Int. J. Rad. Appl. Instrum. [A], 1992, 43, 1383-1385.
330. 11C]methyl triflate. Nucl Med Biol., 1999, 26, 467-471.
331. 11C]methyl triflate. Nucl. Med. Biol., 1995, 22, 235-239.
332. 11C]methyl triflate. J. Label. Compd. Radiopharm., 1998, 41, 545-556.
333. Luthra, S.K.; Pike, V.W.; Brady F. The preparation of carbon- 11 labelled diprenorphine: a new radioligand for the study of the opiate receptor system in vivo. J. Chem. Soc.; Chem. Commun., 1985, 1423-1425.
334. 11C]acid chlorides as labelling agents. J. Labelled Comp. Radiopharm.,1990, 26, 471-476.
335. 11C-carbonyl]-WAY100635. Nucl. Med. Biol., 1999, 26, 815-819.
336. 11C-carboxylation of an immobilized Grignard reagent. J. Labelled Comp. Radiopharm., 1996, 38, 941-953.
337. 11CO carbonylation apparatus. J. Labelled Comp. Radiopharm., 2015, 58, 220-225.
338. 11C-labelled aromatic ketones. Appl. Radiat. Isot., 1997, 48, 1091-1095.
339. 11C]carbon monoxide in labeling synthesis. PCT Int. Appl., 2002 [WO2002/102711].
340. 11C]carbonylation reactions. Chem. Commun., 2009, 25, 3696-698.
341. 11C]carbonylation reactions. Chem. Commun., 2015, 51, 11795-11797.
342. 11C-carbonylation. J. Labelled Com. Radiopharm., 2012, 55, 223-228.
343. 11C]Carbon monoxide, a versatile and useful precursor in labelling chemistry for PET ligand development. J. Labelled Comp. Radiopharm., 2007, 50, 794-810.
344. 11C]carbonylation reactions: recent advances and applications. J. Labelled Comp. Radiopharm., 2014, 57, 195-201.
345. 11C]Carbon monoxide in labeling chemistry and positron emission tomography tracer development: scope and limitations. J. Labelled Comp. Radiopharm., 2015, 58, 86-98.
346. 11C]FIMX) is an effective radioligand for PET imaging of metabotropic glutamate receptor 1 (mGluR1) in monkey brain. Nucl. Med. Biol., 2015, 42, 967-974.
347. 11C-labelled aromatic compounds. J. Chem. Soc. Perkin Trans. 1, 1994, 1, 1395-400.
348. 11C]SP203 as a radioligand for imaging brain metabotropic glutamate 5 receptors. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 1949-1958
349. Shea, C.; Alexoff, D.L.; Kim, D.; Hoque, R.; Schueller, M.J.; Fowler, J.S.; Qu, W. Total cyanide mass measurement with micro-ion selective electrode for determination of specific activity of carbon-11 cyanide. Appl. Radiat. Isot., 2015, 102, 48-54.
350. 11C formaldehyde; an approach. J. Labelled Comp. Radiopharm., 1980, 17, 59-71.
351. 11C]formaldehyde. Angew. Chem. Int. Ed., 2008, 47, 5989-5992.
352. 11C]ethyl labelled radiopharmaceuticals. Appl. Radiat. Isot., 1986, 37, 279-282.
353. 11Clabeled ethyl propyl, butyl and isobutyl iodides and examples of alkylation reactions. Appl. Radiat. Isot., 1986, 37, 1141-1145.
354. 11C]nitroalkanes. Appl. Radiat. Isot., 1989, 40, 261-262.
355. Berger, G.; Mazière, M.; Prenant, C.; Comar, D. Synthesis of carbon-11 labeled acetone. Int. J. Appl. Radiat. Isot., 1980, 31, 577-578.
356. Landais, P.; Crouzel, C. A new synthesis of carbon-11 labeled phosgene. Appl. Radiat. Isot., 1987, 38, 297-300.
357. 11C-phosgene without added carrier. Radiochem. Radioanal. Lett., 1978, 33, 175-178.
358. 11C]phosgene synthesis. Tetrahedron Lett., 2010, 51, 313-316.
359. 11C]Phosgene: a versatile reagent for radioactive carbonyl insertion into medicinal radiotracers for positron emission tomography. Curr. Top. Med. Chem., 2010, 10, 1680-1700.
360. 11C]-labelled aldehydes. Acta Chem. Scand. B, 1984, 38, 1-4.
361. 11C-labeled substituted benzyl iodides. J. Labelled Comp. Radiopharm., 1989, 26, 251-252.
362. 11C]benzyl iodide in positron emission tomography radiotracer production. J. Labelled Comp. Radiopharm., 2015, 58, 342-348.
363. Guillaume, M.; Luxen, A.; Nebeling, B.; Argentini, M.; Clark, J.C.; Pike, V.W. Recommendations for fluorine-18 production. Appl. Radiat. Isot., 1991, 42, 749-762.
364. Berridge, M.S.; Apana, S.M.; Hersch, J.M. Teflon radiolysis as the major source of carrier in fluorine-18. J. Label. Compd. Radiopharm., 2009, 52, 543-548.
365. 18F]fluoropropyl)- 2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl. Med. Biol., 1995, 22, 283-296.
366. Hamill, T.G.; Krause, S.; Ryan, C.; Bonnefous, C.; Goverk, S.; Seiderts, T.J.; Cosford, N.D.; Roppe, J.; Kamenecka, T.; Patel, S.; Gibson, R.E.; Sanabria S.; Riffel, K.; Eng, W.; King, C.; Yang, X.; Green, M.D.; Hargreaves, R.; Burns, H.D. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse, 2005, 56, 205-216
367. Dollé, F. Fluorine-18-labelled fluoropyridines: advances in radiopharmaceutical design. Curr. Pharm. Des., 2005, 11, 3221-3235.
368. 18Flabeling. Org. Lett., 2015, 17, 3726-3729.
369. 18F]fluoroarenes. J. Chem. Soc., Chem. Commun., 1995, 2215-2216.
370. 18F]fluoride ion with diaryliodonium salts. J. Org. Chem., 2010, 75, 3332-3338.
371. th.
372. Rotstein, B.H.; Stephenson, N.A.; Vasdev, N.; Liang, S.H. Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics. Nat. Commun., 2014, 5, 1-7.
373. Yusubov, M.S.; Svitch, D.Y.; Larkina, M.S.; Zhdankin, V.V. Applications of iodonium salts and iodonium ylides as precursors for nucleophilic fluorination in positron emission tomography. Arkivoc, 2013 (i) 364-395.
374. 18F]fluoride into electron-rich arenes. Curr. Org. Chem., 2013, 17, 2921-2935.
375. 18F Labeling of arenes. Angew. Chem. Int. Ed., 2012, 51, 11426-11437.
376. 18F]flumazenil from iodonium tosylate using a sample pretreatment method: a 2.5-year production report. Mol. Imaging Biol. 2014, 16, 619-625.
377. 18F]fluorination of (mesityl)(aryl)iodonium salts. Org. Lett., 2014, 16, 3224-3227.
378. 18F]fluorination of boronic acids. Org. Lett., 2015, 17, 5780-5783.
379. Tredwell, M.; Preshlock, S.; Taylor, N.J.; Gruber, S.; Huiban, M.; Passchier, J.; Mercier, J.; Genicot, C.; Gouverneur, V. A general copper-mediated nucleophilic F-18 fluorination of arenes. Angew. Chem. Int. Ed., 2014, 53, 7751-7755.
380. 18Fbased radiotracers for positron emission tomography. Med. Chem. Comm., 2015, 6, 1714-1754.
381. 18F]Fluoroalkyl agents: synthesis, reactivity and application for development of PET ligands in molecular imaging. Curr. Top. Med. Chem., 2007, 7, 1817-1828.
382. Wuest, F. In: PET Chemistry - The Driving Force in Molecular Imaging. Schubiger, P.A.; Lehmann, L.; Friebe, M., Eds.; Springer: New York, 2007; Ch. 3 pp. 52-78.
383. 18F]trifluoromethyl groups. Chem. Commun., 2011, 47, 11873-11875.
384. 18F]trifluoromethane and its application in the synthesis of PET tracers. Chem. Commun., 2013, 49, 4018-4020.
385. 18F]trifluoromethylation of aryl and heteroaryl iodides for PET imaging. Nat. Chem., 2013, 5, 941-944.
386. 18F]trifluoroalkyl groups: scope and limitations. BioMed. Res. Int., 2014, 2014, 380124. doi: 10.1155/2014/380124.
387. 18F-trifluoromethylation of arenes. Chem. Commun., 2014, 50, 6056-6059.